OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Sensorineural Hearing Loss

In brief

The purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy of OTO-413 administered as an intratympanic injection for the treatment of speech-in-noise hearing impairment.

Key facts

Study ID
NCT04129775
Run by
Otonomy, Inc.
People needed
110
Starts
2019-10-01
Expected to finish
2022-09-05
Last updated by the study team
2022-10-27

Who can join

Age: 21 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.